epiregulin


Also found in: Wikipedia.

epiregulin

A member of the epidermal growth family which is encoded by EREG  on chromosome 4q13.3. It is a ligand of the EGF receptor (EGFR) and ERBB4; it may mediate localised cell proliferation, and may stimulate cell proliferation and/or angiogenesis.

epiregulin

(ep″ē-reg′yŭ-lin)
When released by a cell, an epidermal growth factor that stimulates the cell itself and other cells similar in structure and function to it. It is released in excessive quantities by cancerous cells and fosters their growth and spread throughout the body.
Mentioned in ?
References in periodicals archive ?
On the other hand, proliferative or synthetic SMCs show altered protein expression including increased expression of low-molecular weight caldesmon (l-caldesmon), c-fos, Egr-1, epiregulin, and SMemb MHC (Sobue et al.
It also includes TGF-alpha, Betacellulin, Epigen, Epiregulin, Amphiregulin, Heparin binding EGF.
Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab.
Previous studies indicated that the epiregulin, as well as the betacellulin, were induced by LH in granulose cells and then, via a paracrine mechanism, activated EGF receptor (EGFR) present in cultured murine COCs (Pakarainen et al.
Gene expression profiles showed that patients with tumours that express high levels of the EGFR ligands epiregulin and amphiregulin are more likely to have disease control with cetuximab.
Researchers found that the epiregulin, matrix metallopeptidase 1 and 2, and cyclooxygenase-2 genes produce proteins that combine to stimulate the formation of new blood vessels, enabling cancer cells to escape into the bloodstream and lungs.
The rogues' gallery includes an inflammatory enzyme called cyclooxygenase 2 (COX2), a protein known as epiregulin that's involved in cell growth, and two enzymes that have been implicated in the growth of new blood vessels that nourish tumors.
Expression of epiregulin and amphiregulin and K-RAS mutation status may predict disease control in metastatic colorectal cancer patients treated with cetuximab (ERBITUX([R])); #5671 Lievre et al.
There is evidence that the EGFR ligands epiregulin and amphiregulin are important for prediction of response to cetuximab.
Expression of epiregulin and amphiregulin and K-ras mutation status predictdisease control in metastatic colorectal cancer patients treated with cetuximab.